SLC5A2 and peripheral arterial disease: If the increased risk of amputations in PAD patients treated with canagliflozin was confirmed, considering the promising data on the protective role of SGLT2-i on neurological, vascular, and immunomodulatory complications, it could be hypothesized that the dual detrimental and beneficial effect could depend on the duration of the disease and on the moment of the natural history in which the drug is inserted.